Literature DB >> 28138817

Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre.

Sorin Giusca1, Derliz Mereles1, Andreas Ochs1, Sebastian Buss1, Florian André1, Sebastian Seitz1, Johannes Riffel1, Philipp Fortner1, Mindaugas Andrulis2, Stefan Schönland3, Hugo A Katus1, Grigorios Korosoglou4.   

Abstract

To assess the value of cardiac magnetic resonance imaging (CMR) in evaluating cardiac tumours in a tertiary cardiology centre. Between 2004 and 2014, 125 patients (pts.) from a total of 17000 who received a CMR examination in our institution were referred with the suspicion of cardiac tumours. A dedicated protocol was used that included standard cine SSFP acquisitions as well as tissue characterization using T1 and T2 black-blood (T1 BB and T2 BB respectively) with and without fat suppression, perfusion of the structure and late gadolinium enhancement. Patients' files were retrospectively analysed and data related to clinical status, results from other examinations (echocardiography), therapeutic approach and histology results, when performed, were collected. In 65 pts., a diagnosis of cardiac tumour was reached. 45 Pts had a biopsy. The CMR examination was concordant with the histology results in 35 (76%) pts. superior to that showed by echocardiography, 26 (58%) pts., p = 0.03. Forty-two (65%) pts. had a benign tumour and 23 (35%) a malignant process. Myxoma was the most frequent benign tumour, 27 (65%) and cardiac metastases were the most frequent form of malignancies, 21 (91%), with B cell non-Hodgkin lymphoma being the most frequent one, 4 (19%). Benign tumours were mostly located in the left atrium, 27 (64%) versus 6 (26%), p = 0.007, whereas malignant tumours had a predilection for the right atrium und left ventricle [11 (48%) vs. 3 (7%), p = 0.001 and 8 (35%) vs. 3 (7%), p = 0.03]. All benign cardiac tumours were single and did not show signs of infiltration. Conversely, malignant cardiac tumours were larger (43 ± 35 vs. 24 ± 16, p = 0.007) with a significant proportion (65%) showing myocardial infiltration. Pts with malignant cardiac tumours had a higher proportion of LGE (82 vs. 60%, p = 0.05) and exhibited more frequently an isointense signal in T1 BB images (78 vs. 61%, p = 0.04). Both groups showed similar proportion of perfusion and signal intensity in the T2 BB acquisitions (p = NS). CMR is a valuable tool in evaluating cardiac tumours, proving superior to echocardiography in establishing the type of cardiac tumour.

Entities:  

Keywords:  Cardiac metastasis; Cardiac tumour; Late gadolinium enhancement; Myxoma; Tissue characterisation

Mesh:

Substances:

Year:  2017        PMID: 28138817     DOI: 10.1007/s10554-017-1065-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  34 in total

1.  Cardiovascular magnetic resonance imaging for diagnosis and clinical management of suspected cardiac masses and tumours.

Authors:  Sandra Fussen; Bart W L De Boeck; Michael J Zellweger; Jens Bremerich; Kaatje Goetschalckx; Michel Zuber; Peter T Buser
Journal:  Eur Heart J       Date:  2011-04-15       Impact factor: 29.983

2.  CMR in the assessment of cardiac masses: primary malignant tumors.

Authors:  Antonio Esposito; Francesco De Cobelli; Gabriele Ironi; Paolo Marra; Tamara Canu; Renata Mellone; Alessandro Del Maschio
Journal:  JACC Cardiovasc Imaging       Date:  2014-10

3.  Value of CMR for the differential diagnosis of cardiac masses.

Authors:  Pablo Pazos-López; Eduardo Pozo; Maria E Siqueira; Inés García-Lunar; Matthew Cham; Adam Jacobi; Frank Macaluso; Valentín Fuster; Jagat Narula; Javier Sanz
Journal:  JACC Cardiovasc Imaging       Date:  2014-08-13

4.  Primary cardiac tumors: early and late results of surgical treatment in 91 patients.

Authors:  P Centofanti; E Di Rosa; L Deorsola; G M Dato; F Patanè; M La Torre; L Barbato; A Verzini; G Fortunato; M di Summa
Journal:  Ann Thorac Surg       Date:  1999-10       Impact factor: 4.330

Review 5.  Cardiac myxoma: imaging features in 83 patients.

Authors:  Mary L Grebenc; Melissa L Rosado-de-Christenson; Curtis E Green; Allen P Burke; Jeffrey R Galvin
Journal:  Radiographics       Date:  2002 May-Jun       Impact factor: 5.333

6.  Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation.

Authors:  Monvadi B Srichai; Chelif Junor; L Leonardo Rodriguez; Arthur E Stillman; Richard A Grimm; Michael L Lieber; Joan A Weaver; Nicholas G Smedira; Richard D White
Journal:  Am Heart J       Date:  2006-07       Impact factor: 4.749

7.  Cardiac myxoma: a 13-year experience in echocardiographic diagnosis.

Authors:  Ricardo Oliveira; Luisa Branco; Ana Galrinho; Ana Abreu; João Abreu; Antonio Fiarresga; Andreia Mamede; Ruben Ramos; Ana Leal; Eugénia Pinto; José Fragata; Rui Ferreira
Journal:  Rev Port Cardiol       Date:  2010 Jul-Aug       Impact factor: 1.374

8.  Radical resection of cardiac sarcoma.

Authors:  A Hoffmeier; S Deiters; C Schmidt; T D T Tjan; C Schmid; G Drees; E M Fallenberg; H H Scheld
Journal:  Thorac Cardiovasc Surg       Date:  2004-04       Impact factor: 1.827

Review 9.  Cardiac tumors: optimal cardiac MR sequences and spectrum of imaging appearances.

Authors:  David H O'Donnell; Suhny Abbara; Vithaya Chaithiraphan; Kibar Yared; Ronan P Killeen; Ricardo C Cury; Jonathan D Dodd
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

10.  Cardiac tumors: the experience of a tertiary cardiology center.

Authors:  S Giuşcă; Ruxandra Jurcuţ; Marinela Serban; B A Popescu; E Apetrei; Carmen Ginghină
Journal:  Rom J Intern Med       Date:  2007
View more
  8 in total

1.  Cardiovascular imaging 2017 in the International Journal of Cardiovascular Imaging.

Authors:  Johan H C Reiber; Amer Alaiti; Hiram G Bezerra; Johan De Sutter; Paul Schoenhagen; Arthur E Stillman; Nico R L Van de Veire
Journal:  Int J Cardiovasc Imaging       Date:  2018-06       Impact factor: 2.357

Review 2.  Cardiac myxoma: a contemporary multimodality imaging review.

Authors:  Geoffrey C Colin; Bernhard L Gerber; Mihaela Amzulescu; Jan Bogaert
Journal:  Int J Cardiovasc Imaging       Date:  2018-07-04       Impact factor: 2.357

Review 3.  Cardiac Tumors: Clinical Presentation, Diagnosis, and Management.

Authors:  Timothy J Poterucha; Jonathan Kochav; Daniel S O'Connor; Gregg F Rosner
Journal:  Curr Treat Options Oncol       Date:  2019-06-27

4.  Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study.

Authors:  Chetan Shenoy; John D Grizzard; Dipan J Shah; Mahwash Kassi; Michael J Reardon; Marianna Zagurovskaya; Han W Kim; Michele A Parker; Raymond J Kim
Journal:  Eur Heart J       Date:  2021-12-28       Impact factor: 35.855

5.  Cutting-Edge Imaging of Cardiac Metastases from Neuroendocrine Tumors: Lesson from a Case Series.

Authors:  Soraya El Ghannudi; Eric Ouvrard; Nidaa Mikail; Benjamin Leroy Freschini; Thomas H Schindler; Alessio Imperiale
Journal:  Diagnostics (Basel)       Date:  2022-05-09

6.  Syncope in a female patient. Echocardiography and cardiac computed tomography reveal an unexpected diagnosis.

Authors:  Sorin Giusca; Sebastian Buss; Felix Lasitschka; Matthias Karck; Grigorios Korosoglou
Journal:  Clin Case Rep       Date:  2019-05-07

7.  The diagnostic accuracy of contrast echocardiography in patients with suspected cardiac masses: A preliminary multicenter, cross-sectional study.

Authors:  Ying Li; Weidong Ren; Xin Wang; Yangjie Xiao; Yueqin Feng; Pengli Shi; Lijuan Sun; Xiao Wang; Huan Yang; Guang Song
Journal:  Front Cardiovasc Med       Date:  2022-09-16

8.  The diagnostic performance of magnetic resonance imaging for differentiating the nature of cardiac masses: A systematic review protocol.

Authors:  Jin-Rong Ni; Yuan Hu; Li-Ping Shao; Bing Song; Yuan-Min Li; Jun-Qiang Lei
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.